EP3668606B1 - Method of controlling staining of teeth due to cationic antimicrobial agent - Google Patents
Method of controlling staining of teeth due to cationic antimicrobial agent Download PDFInfo
- Publication number
- EP3668606B1 EP3668606B1 EP18739865.6A EP18739865A EP3668606B1 EP 3668606 B1 EP3668606 B1 EP 3668606B1 EP 18739865 A EP18739865 A EP 18739865A EP 3668606 B1 EP3668606 B1 EP 3668606B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composite material
- chloride
- use according
- clay
- bipolar composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010186 staining Methods 0.000 title claims description 8
- 239000004599 antimicrobial Substances 0.000 title description 19
- 125000002091 cationic group Chemical group 0.000 title description 9
- 238000000034 method Methods 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 80
- 239000004927 clay Substances 0.000 claims description 29
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 27
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 27
- 239000002245 particle Substances 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 24
- 150000001768 cations Chemical class 0.000 claims description 21
- 239000000606 toothpaste Substances 0.000 claims description 21
- 239000002131 composite material Substances 0.000 claims description 20
- 230000000845 anti-microbial effect Effects 0.000 claims description 18
- 229940034610 toothpaste Drugs 0.000 claims description 15
- 239000002324 mouth wash Substances 0.000 claims description 12
- -1 quaternium Chemical compound 0.000 claims description 12
- 229940051866 mouthwash Drugs 0.000 claims description 11
- 239000002243 precursor Substances 0.000 claims description 10
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 9
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052622 kaolinite Inorganic materials 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 4
- 229960001950 benzethonium chloride Drugs 0.000 claims description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 4
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims description 3
- 150000003868 ammonium compounds Chemical class 0.000 claims description 3
- 229910052619 chlorite group Inorganic materials 0.000 claims description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 3
- YGKOYVNJPRSSRX-UHFFFAOYSA-M (4-dodecylphenyl)methyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC1=CC=C(C[N+](C)(C)C)C=C1 YGKOYVNJPRSSRX-UHFFFAOYSA-M 0.000 claims description 2
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 claims description 2
- GKQHIYSTBXDYNQ-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 GKQHIYSTBXDYNQ-UHFFFAOYSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims description 2
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 claims description 2
- 229960002798 cetrimide Drugs 0.000 claims description 2
- 229910001919 chlorite Inorganic materials 0.000 claims description 2
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001378 dequalinium chloride Drugs 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960001859 domiphen bromide Drugs 0.000 claims description 2
- VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 claims description 2
- 229960002285 methylbenzethonium chloride Drugs 0.000 claims description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000000551 dentifrice Substances 0.000 description 14
- 210000000214 mouth Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003906 humectant Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 5
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000003082 abrasive agent Substances 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000003801 milling Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229910021647 smectite Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 241000178435 Eliokarmos dubius Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 241000876852 Scorias Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000002882 anti-plaque Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000012243 magnesium silicates Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- MCNJOIMMYWLFBA-UHFFFAOYSA-N 2-dodecoxy-2-oxoethanesulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCCOC(=O)CS(O)(=O)=O MCNJOIMMYWLFBA-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical compound [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229910001579 aluminosilicate mineral Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- HPTYUNKZVDYXLP-UHFFFAOYSA-N aluminum;trihydroxy(trihydroxysilyloxy)silane;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O[Si](O)(O)O HPTYUNKZVDYXLP-UHFFFAOYSA-N 0.000 description 1
- 229910001588 amesite Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052599 brucite Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910001649 dickite Inorganic materials 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical group COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229910052621 halloysite Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 229910052899 lizardite Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052615 phyllosilicate Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229940032044 quaternium-18 Drugs 0.000 description 1
- 229940101631 quaternium-18 hectorite Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 229940070720 stearalkonium Drugs 0.000 description 1
- 125000005502 stearalkonium group Chemical group 0.000 description 1
- 229940102548 stearalkonium hectorite Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical class [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000036344 tooth staining Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- IBPRKWGSNXMCOI-UHFFFAOYSA-N trimagnesium;disilicate;hydrate Chemical compound O.[Mg+2].[Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IBPRKWGSNXMCOI-UHFFFAOYSA-N 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61Q11/02—Preparations for deodorising, bleaching or disinfecting dentures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0254—Platelets; Flakes
- A61K8/0258—Layered structure
- A61K8/0266—Characterized by the sequence of layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/65—Characterized by the composition of the particulate/core
- A61K2800/651—The particulate/core comprising inorganic material
Definitions
- the present invention relates to a method of controlling or minimising stains on teeth due to use of oral care products comprising cationic antimicrobial agent.
- Oral care compositions usually contain one or more antimicrobial agent, examples include compounds of zinc, Triclosan and Nitrogen-based cationic compounds like Cetyl pyridinium chloride (CPC).
- antimicrobial agent examples include compounds of zinc, Triclosan and Nitrogen-based cationic compounds like Cetyl pyridinium chloride (CPC).
- CPC Cetyl pyridinium chloride
- cationic antimicrobial agents are well known for their action against bacteria in the oral cavity to help prevent, or at least minimize the formation of plaque.
- Benzethonium chloride, chlorhexidine and CPC are used more commonly, in mouthwash compositions.
- bleach acts by oxidizing color bodies and the existing stains. However, this would mean targeting the effect rather than the cause.
- WO13192463 A1 discloses the use of anti-stain agents from each of at least two of the following chemical groups, viz, anionic agents, carbonyl compounds and nonionic ethoxylated surfactants.
- the agents are able to reduce aggregation of salivary proteins, either by direct hydrophobic or charged interaction of the anionic agent with the salivary proteins or by the formation of a counter ion with the pyridinium ring of CPC.
- the anionic agent is more tightly bound to the pyridinium ring than the chloride ion, which then reduces the interaction of CPC with the salivary proteins.
- Aldehydes react with salivary proteins by forming thioacetals reduce the negative charge density on the surface of the protein and thus, the protein interaction with the positively charged pyridinium ring of CPC.
- the combination enables stronger interaction between the aldehyde and the protein compared to the interaction between the protein and CPC, as CPC is now tightly bound to a large anionic counter ion and thus less available to interact with the protein.
- Ethoxylates having the right balance of alkyl and ethoxy units solubilize the salivary proteins, thereby reducing staining.
- JP2011201861A discloses the use of one or more kinds of OH-containing compounds selected from the group consisting of thymol, isopropylmethylphenol, terpineol, eugenol, linalool, geraniol and citronellol one or more kinds of diols selected from hexane diol and octane diol to solve the problem of staining.
- JP2011153138A (Sunstar ) the problem is solved by including glycyrrhizic acid or its salt.
- JP2011148706A (Sunstar INC ) the problem is solved by use of butanediol, pentanediol, hexanediol or octanediol.
- WO2014102032 A1 discloses a ⁇ n oral care composition having: (i) 5 to 60 wt% abrasive; (ii) an anionic surfactant; and, (iii) a bipolar antimicrobial particle whose precursor is an asymmetric 1:1 or 2:1:1 clay particle comprising alternating tetrahedral and octahedral sheets terminating with a tetrahedral sheet at one external surface plane and an octahedral sheet at another external surface plane with an antimicrobial agent attached to the coordinating cation on one of the said external surface plane where the antibacterial agent is a quaternary ammonium material.
- the disclosed compositions are highly effective at controlling bacterial re-growth, as well as they are equally good at providing immediate control on the bacterial count.
- KR20160050126 A discloses a toothpaste composition using a scoria powder. Specifically, disclosed is a toothpaste composition for teeth whitening, comprising a scoria powder having a teeth whitening effect as a polishing agent, thereby having a teeth whitening effect.
- US4370314 A discloses oral hygiene composition containing a cationic quaternary ammonium antibacterial antiplaque agent and an additive which reduces staining of dental surfaces without unduly diminishing the antibacterial and antiplaque activity of the agent, which additive is an alkali metal hexametaphosphate or mixture thereof with alkali metal bicarbonate.
- Quaternary ammonium salts include benzethonium chloride and cetyl pyridinium chloride.
- the antimicrobial quaternary ammonium compound is in the form of a bipolar composite material comprising a specific type of clay and the ammonium compound.
- a bipolar composite material comprising:
- Cationic antimicrobial agents which are known for their propensity to stain teeth include quaternary ammonium salts, chlorohexidine and bis-biquanide salts. While on the one hand, their efficacy against undesired oral microflora makes them suitable for use in oral care compositions such as mouthwash and toothpastes, the side effect is responsible, at least in part, for their lack of popularity. If one still desires to use such products to benefit from their primary effect, the secondary effects needs to be toned down by the use of one or more additional agents disclosed in the compositions forming state of the art. These additional agents may pose some secondary problems of their own such as the possibility of altering the taste, flavor impact or stability of the compositions.
- the present invention is a non-obvious solution to the problem, whilst still retaining the essential functional and consumer-relevant attributes of oral care compositions.
- the problem has been solved by identifying the use of antimicrobial material.
- the solution in the present invention lies in the inclusion of the composite material which acts as a carrier of the cationic antimicrobial agent.
- the composite material is based on an inert material which does not affect the important properties of the compositions.
- the Applicant has disclosed that the bipolar antimicrobial material is highly effective at controlling re-growth of bacteria, as well as at providing immediate control on the bacterial count.
- median particle size (D50) of this material is 0.1 to 10 ⁇ m, more preferably 0.4 to 1 ⁇ m and most preferably 0.5 to 0.8 ⁇ m. Without being bound by theory, it is believed that this makes more effective use of the antimicrobial agent, thereby providing opportunity for substantial reduction in dosage of the antibacterial agent. While conventional antibacterial agents need an optimised dosage of 0.2 to 0.5 wt%, the antibacterial agent, delivered in the form of the bipolar antibacterial material, is effective even at an (actual) dosage of 0.02 wt% of the oral care compostion, insofar as the antimicrobial effect is concerned.
- Particle size distribution is also known as the median diameter or the medium value of the particle size distribution, it is the value of the particle diameter at 50 percent in the cumulative distribution. For example, if D50 is 5.8 ⁇ m, then 50 % of the particles in the sample are larger than 5.8 ⁇ m and 50 percent smaller than 5.8 ⁇ m. D50 is usually used to represent the particle size of group of particles. The D50 is the size in microns that splits the distribution with half above and half below this diameter.
- the precursor of the clay is an asymmetric 1:1 clay particle.
- Preferred 1:1 clays include kaolinite and serpentine subgroups of minerals.
- the species included within the kaolinite subgroup include but are not limited to kaolinite, dickite, halloysite and nacrite.
- the species within the serpentine subgroup include but are not limited to chrysolite, lizardite, and amesite.
- the precursor of the clay is an asymmetric 2:1:1 clay particle.
- Preferred 2:1:1 clays include chlorite group of minerals.
- the chlorite comprises tetrahedral-octahedral-tetrahedral sheets like 2:1 clays, with an extra weakly bound brucite like layer between tetrahedral layers.
- the tetrahedral sheet preferably comprises coordinating tetrahedral cations of silicon.
- the tetrahedral sheet may also include isomorphously substituted coordinating tetrahedral cations which are not silicon. Isomorphously substituted coordinating tetrahedral cations include, but are not limited to, cations of aluminum, iron or boron.
- the octahedral sheet has coordinating octahedral cations of aluminum.
- the octahedral sheet may also comprise isomorphously substituted coordinating octahedral cations which are not aluminium. Isomorphously substituted coordinating octahedral cations include cations of magnesium and iron.
- the antimicrobial agent is attached to the coordinating cations on the exterior side of one of the external surface planes. Accordingly, the antimicrobial agent is attached to coordinating cations on the exterior side of the tetrahedral sheet. Alternatively, the antimicrobial molecule is attached to the coordinating cations on the exterior side of the octahedral sheet.
- Coordinating cations on the exterior side of each of the tetrahedral and the octahedral surface sheets are attached to the antimicrobial agent, with the proviso that the antimicrobial agent attached to the coordinating cations on the exterior side of the tetrahedral surface sheet is not identical to the molecule attached to the coordinating cations on the exterior side of the octahedral surface sheet.
- the antimicrobial agent is preferably attached to the coordinating cations on the external surface of the octahedral surface plane and is not preferably attached to coordination cations of non-exterior tetrahedral or octahedral plane or on the interior side of the surface sheets.
- the ratio of the clay: antimicrobial agent is from 1:0.001 to 1:1, more preferably from 1:0.001 and 1:0.1 parts by weight of the bipolar composite material.
- the antibacterial agent is attached to coordinating cations on the external surface of the octahedral surface plane.
- oral care compositions of the invention comprise 0.1 to 10 wt% of the bipolar antimicrobial material, more preferably 0.5 to 5 wt% material.
- the quaternary ammonium compound is one or more of cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), benzethonium chloride, cetrimide, quaternium, tetrabutyl ammonium bromide, undecylenamido propyltrimonium methosulphate, methylbenzethonium chloride, cetethyldimonium bromide, cetromonium tosylate, cocotrimonium chloride, dodecylbenzyltrimonium chloride, lauryl isoquinolium bromide, laurylpyridinium chloride, dequalinium chloride or domiphen bromide.
- CPC cetylpyridinium chloride
- CTC cetyltrimethylammonium chloride
- CTAB cetyltrimethylammonium bromide
- cetylpyridinium chloride cetylpyridinium chloride
- the primary activity is linked to the cationic charge of its amine group.
- cetylpyridinium chloride is attracted to and binds to negatively-charged protein moieties on the cell membrane or cell wall of the microorganism and to tooth surfaces which are also typically negatively charged.
- the resulting attachment to microorganisms disrupts the cell wall structure causing leakage of the intracellular fluids, eventually killing the associated microorganism.
- cetylpyridinium chloride its tendency to stain the teeth has largely been responsible for the lack of popularity of oral compositions which contain for example and in particular, CPC.
- precursor of the clay is a 1:1 clay particle. Further preferably the precursor of the clay is kaolinite. It is particularly preferred that the antimicrobial quaternary ammonium compound is cetyl pyridinium chloride. It is further particularly preferred that when the precursor of the clay is kaolinite, the antimicrobial quaternary ammonium compound is cetyl pyridinium chloride.
- the oral care composition is a toothpaste.
- the oral care composition is a mouthwash.
- Other known forms include toothpowder, chewing gums and lozenges, strips and gels.
- the oral care composition according to the invention is a toothpaste
- the toothpaste comprises at least one of calcium-based abrasive or silica-based abrasive.
- Toothpastes are also known as dentifrices.
- the term "dentifrice” generally denotes formulations which are used to clean the surfaces of the oral cavity.
- the dentifrice is an oral composition that is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is applied to the oral cavity, used to treat the oral cavity and then expectorated.
- the dentifrice is used in conjunction with a cleaning implement such as a toothbrush, usually by applying it to the bristles of the toothbrush and then brushing the accessible surfaces of the oral cavity.
- a cleaning implement such as a toothbrush
- the dentifrice is in the form of a paste or a gel (or a combination thereof).
- An oral care composition according to the invention will usually contain a liquid continuous phase in an amount of from 40 to 99% by weight based on the total weight of the dentifrice.
- a liquid continuous phase will typically comprise a mixture of water and polyhydric alcohol in various relative amounts, with the amount of water generally ranging from 10 to 45% by weight (based on the total weight of the dentifrice) and the amount of polyhydric alcohol generally ranging from 30 to 70% by weight (based on the total weight of the dentifrice).
- Humectants are generally included in toothpastes for a soft, supple mouth feel. Humectants also reduce the tendency of toothpastes to lose moisture.
- Preferred toothpaste compositions contain 3.5 to 40 wt% humectants. Further preferred compositions have 10 to 40 wt%, more particularly 10 to 20 wt% humectants.
- a particularly preferred humectant is sorbitol, generally available as 70% aqueous solution. Other preferred humectants include glycerine, maltitol and xylitol. More preferred toothpastes contain glycerine and sorbitol for a lubricated mouth feel, but their cumulative levels should not exceed the disclosed upper limit. Lower humectant content provides an effective way to reduce the cost of the product.
- An oral care composition according to the invention will generally contain further ingredients to enhance performance and/or consumer acceptability such as abrasive cleaning agent, binder or thickening agent, and surfactant.
- a dentifrice will usually comprise an abrasive cleaning agent in an amount of from 3 to 75% by weight based on the total weight of the dentifrice.
- Suitable abrasive cleaning agents include silica xerogels, hydrogels and aerogels and precipitated particulate silicas; calcium carbonate, dicalcium phosphate, tricalcium phosphate, calcined alumina, sodium and potassium metaphosphate, sodium and potassium pyrophosphates, sodium trimetaphosphate, sodium hexametaphosphate, particulate hydroxyapatite and mixtures thereof.
- abrasives examples include abrasive amorphous silica particles which have a weight mean particle size (d50) ranging from 3 to 15 microns.
- Preferred abrasive amorphous silica particles for use in the composition of the invention have a weight mean particle size in the range 3 to 6 microns.
- the abrasive amorphous silica particles employed are precipitated silica.
- Suitable precipitated silicas for use as abrasive amorphous silica particles in the invention are commercially available and include those marketed by PQ Corporation under the trade names SORBOSIL ® AC 43, AC77, AC35 and SORBOSIL ® AC 33. Mixtures of any of the above described materials may also be used.
- the level of abrasive amorphous silica particles generally ranges from 0.05 to 5%, preferably from 0.1 to 3%, more preferably from 0.2 to 0.8%, by total weight abrasive amorphous silica particles (as defined above) based on the total weight of the composition.
- compositions of the invention comprise calcium-based abrasive.
- a particularly preferred abrasive is fine ground natural chalk (FGNC). It is obtained from limestone or marble.
- FGNC may also be modified chemically or physically by coating during or after milling by heat treatment. Typical coating materials include magnesium stearate and oleate.
- the morphology of FGNC may also be modified during the milling process by using different milling techniques, for example, ball milling, air-classifier milling or spiral jet milling.
- FGNC can be used as the sole calcium containing abrasive. However, FGNC can also be used with other calcium containing abrasives to balance the abrasion.
- FGNC dicalcium phosphate
- PCC precipitated calcium carbonate
- compositions of the invention preferably comprise a binder or thickening agent in an amount of from 0.5 to 10% by weight based on the total weight of the dentifrice.
- Suitable binders or thickening agents include carboxyvinyl polymers (such as polyacrylic acids cross-linked with polyallyl sucrose or polyallyl pentaerythritol), hydroxyethyl cellulose, hydroxypropyl cellulose, water soluble salts of cellulose ethers (such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose), natural gums (such as carrageenan, gum karaya, guar gum, xanthan gum, gum arabic, and gum tragacanth), finely divided silicas, hectorites, colloidal magnesium aluminium silicates and mixtures thereof.
- compositions of the invention preferably comprise a surfactant in an amount of from 0.2 to 10% by weight based on the total weight of the dentifrice.
- Suitable surfactants include anionic surfactants, such as the sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl sulphates (for example sodium lauryl sulphate), C8 to C18 alkyl sulphosuccinates (for example dioctyl sodium sulphosuccinate), C8 to C18 alkyl sulphoacetates (such as sodium lauryl sulphoacetate), C8 to C18 alkyl sarcosinates (such as sodium lauryl sarcosinate), C8 to C18 alkyl phosphates (which can optionally comprise up to 10 ethylene oxide and/or propylene oxide units) and sulphated monoglycerides.
- anionic surfactants such as the sodium, magnesium, ammonium or ethanolamine salts of C8
- Suitable surfactants include nonionic surfactants, such as optionally polyethoxylated fatty acid sorbitan esters, ethoxylated fatty acids, esters of polyethylene glycol, ethoxylates of fatty acid monoglycerides and diglycerides, and ethylene oxide/propylene oxide block polymers.
- suitable surfactants include amphoteric surfactants, such as betaines or sulphobetaines. Mixtures of any of the above described materials may also be used.
- oral care compositions of the invention include a smectite clay which is in addition to the clay present by way of the bipolar antimicrobial material.
- Smectites constitute a group in the class of natural aluminosilicate minerals known as phyllosilicates or layered silicates.
- Preferred smectite clay is selected from montmorillonites (bentonites, hectorites and derivatives thereof); purified aluminium magnesium silicates (various grades are commercially available as VEEGUM (R) from R. T.
- Vanderbilt Company purified sodium magnesium silicates (commercially available as LAPONITE (R) in various grades); organically modified smectites including tetra alkyl and/or trialkyl ammonium smectites (organically modified montmorillonite clays) such as quaternium-18 bentonite, quaternium-18 hectorite, stearalkonium bentonite and stearalkonium hectorite/ and mixtures thereof. Aluminium magnesium silicate clays are particularly preferred. An example is VEEGUM (R) HV. The clay tends to swell when exposed to water. Preferred toothpaste compositions contain 0.2 to 3 wt percent clay. More preferred compositions include 0.5 to 1 wt percent clay.
- the smectite clay not only plays a role in sensory profile as is believed, but it also plays a role in thickening the composition, as the reduced content of thickening silica otherwise leads to a product with lower viscosity.
- Oral care compositions of the invention further preferably comprise a zinc salt, preferably zinc sulphate or zinc chloride, more preferably zinc sulphate heptahydrate.
- a zinc salt preferably zinc sulphate or zinc chloride, more preferably zinc sulphate heptahydrate.
- the level of zinc salt is from 0.05 to 1.0 wt% of the total composition more preferably from 0.1 to 0.5 wt%.
- compositions of the invention may comprise a preservative, a preferred preservative is sodium benzoate.
- the level of preservative is from 0.1 to 1 wt% of the total composition. It is preferred that pH of the composition at 20 °C is from 4 to 10, more preferably 7 to 9.
- compositions of the invention may also comprise a deposition aid.
- deposition aid in the context of this invention generally means a material which further aids deposition of whitening agents from the composition.
- An example is polystyrene sulphonates.
- Another example is Gantrez ® polymers.
- mouthwash generally denotes liquid formulations which are used to rinse the surfaces of the oral cavity and provide the user with a sensation of oral cleanliness and refreshment.
- the mouthwash is an oral composition that is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is applied to the oral cavity, used to treat the oral cavity and then expectorated.
- a mouthwash composition will usually contain an aqueous continuous phase.
- the amount of water generally ranges from 70 to 99% by weight based on the total weight of the mouthwash.
- a mouthwash composition according to the invention will generally contain further ingredients to enhance performance and/or consumer acceptability, such as the humectants and surfactants mentioned above for dentifrices.
- the amount of humectant generally ranges from 5 to 20% by weight based on the total weight of the mouthwash and the amount of surfactant generally ranges from 0.1 to 5% by weight based on the total weight of the mouthwash.
- compositions of the present invention may also contain further optional ingredients customary in the art such as fluoride ion sources, anticalculus agents, buffers, flavouring agents, sweetening agents, colouring agents, opacifying agents, preservatives, antisensitivity agents and antimicrobial agents.
- composition in the context of this invention typically involves application of the composition to the oral cavity, for a recommended time, before being expectorated.
- the preferred time application time being from 10 to 60 seconds.
- the compositions were subjected to in-vitro assay following the Bovine Tooth Model, (without brushing).
- the procedure was as follows: This model utilizes extracted bovine teeth mounted on polyacrylate material. Bovine teeth were first bleached with dilute peroxide followed by washing with water. The bleached teeth were incubated with saliva for four hours and dried. The teeth were then imaged to determine their baseline color values (L*a*b*) using digital photography using the white light imaging system (Fuji 2000 Camera). L* represents lightness on the y axis, a* represents chroma (red-green) on the x axis, and b* represents chroma (yellow-blue) on the z axis. The teeth were then incubated in saliva for 18 hours to generate a mature coating of pellicle thereon. The saliva was then removed and the teeth were treated with a slurry of the concerned toothpaste (containing no antimicrobials) for two minutes.
- the toothpaste slurry was removed and the teeth were washed with water for one minute.
- the teeth specimens were then ready for treatment.
- the teeth specimen were treated with CPC solution (positive control), water (negative control) or CPC test rinse solution for one minute in the presence of saliva.
- the teeth were then incubated with saliva for 20 minutes at 35 °C.
- Each specimen was subsequently treated with freshly made aqueous solution of tea for 15 minutes, followed by another washing and incubation with saliva for 20 minutes. A total of six treatment cycles were carried out. After five cycles, the teeth were dried and the L*a*b* values were measured again using photo imaging.
- the observation with the ⁇ E value of the inventive composition is that the ⁇ E value is the same as that of the corresponding Control Composition 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Description
- The present invention relates to a method of controlling or minimising stains on teeth due to use of oral care products comprising cationic antimicrobial agent.
- Oral care compositions usually contain one or more antimicrobial agent, examples include compounds of zinc, Triclosan and Nitrogen-based cationic compounds like Cetyl pyridinium chloride (CPC).
- In particular, cationic antimicrobial agents are well known for their action against bacteria in the oral cavity to help prevent, or at least minimize the formation of plaque.
- Benzethonium chloride, chlorhexidine and CPC are used more commonly, in mouthwash compositions.
- However, their use, in particular, their prolonged use lead to staining or discolouration of teeth. It is believed that the enamel contains high proportion (about 95%) of hydroxyapatite which is a form of calcium phosphate and the phosphate from saliva tends to deposit on teeth which leads to the formation of stains.
- This tendency to stain the teeth is responsible, at least in part, for the lack of popularity of oral care compositions which contain such agents.
- One way to reduce staining is to use of bleach or oxidants such as peroxide. A bleach acts by oxidizing color bodies and the existing stains. However, this would mean targeting the effect rather than the cause.
-
WO13192463 A1 (P&G -
JP2011201861A (Sunstar INC - In
JP2011153138A (Sunstar - In
JP2011148706A (Sunstar INC - In
EP0372603 A2 (Colgate Palmolive, 1990 ), the problem is solved by use of aminoguanidine free base or its water soluble salt. -
WO2014102032 A1 (Unilever ) discloses a \n oral care composition having: (i) 5 to 60 wt% abrasive; (ii) an anionic surfactant; and, (iii) a bipolar antimicrobial particle whose precursor is an asymmetric 1:1 or 2:1:1 clay particle comprising alternating tetrahedral and octahedral sheets terminating with a tetrahedral sheet at one external surface plane and an octahedral sheet at another external surface plane with an antimicrobial agent attached to the coordinating cation on one of the said external surface plane where the antibacterial agent is a quaternary ammonium material. The disclosed compositions are highly effective at controlling bacterial re-growth, as well as they are equally good at providing immediate control on the bacterial count. -
KR20160050126 A (JEJULOVE CO LTD -
US4370314 A (Abdul Gaffar, 1983 ) discloses oral hygiene composition containing a cationic quaternary ammonium antibacterial antiplaque agent and an additive which reduces staining of dental surfaces without unduly diminishing the antibacterial and antiplaque activity of the agent, which additive is an alkali metal hexametaphosphate or mixture thereof with alkali metal bicarbonate. Quaternary ammonium salts include benzethonium chloride and cetyl pyridinium chloride. - However, there is need for further improvised oral care compositions which can solve the problem in an effective yet simple manner and without adversely affecting the antimicrobial action of the cationic agent.
- We have determined that the problem can be solved if the antimicrobial quaternary ammonium compound is in the form of a bipolar composite material comprising a specific type of clay and the ammonium compound.
- In accordance with a first aspect is disclosed a bipolar composite material comprising:
- (i) a clay whose precursor is an asymmetric 1:1 or 2:1:1 clay particle, comprising alternating tetrahedral and octahedral sheets terminating with a tetrahedral sheet at one external surface plane and an octahedral sheet at another; and,
- (ii) antimicrobial quaternary ammonium compound attached to a coordinating cation on one of said external surface planes, for use in an oral care composition, to control staining of teeth due to said ammonium compound.
- These and other aspects, features and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. For the avoidance of doubt, any feature of one aspect of the present invention may be utilised in any other aspect of the invention. The word "comprising" is intended to mean "including" but not necessarily "consisting of" or "composed of." In other words, the listed steps or options need not be exhaustive. It is noted that the examples given in the description below are intended to clarify the invention and are not intended to limit the invention to those examples per se. Similarly, all percentages are weight/weight percentages unless otherwise indicated. Except in the operating and comparative examples, or where otherwise explicitly indicated, all numbers in this description and claims indicating amounts of material or conditions of reaction, physical properties of materials and/or use are to be understood as modified by the word "about". Numerical ranges expressed in the format "from x to y" are understood to include x and y. When for a specific feature multiple preferred ranges are described in the format "from x to y", it is understood that all ranges combining the different endpoints are also contemplated.
- All references to the term/expression wt% or % by weight, shall mean percentage by weight of the composition, except where indicated otherwise.
- Cationic antimicrobial agents which are known for their propensity to stain teeth include quaternary ammonium salts, chlorohexidine and bis-biquanide salts. While on the one hand, their efficacy against undesired oral microflora makes them suitable for use in oral care compositions such as mouthwash and toothpastes, the side effect is responsible, at least in part, for their lack of popularity. If one still desires to use such products to benefit from their primary effect, the secondary effects needs to be toned down by the use of one or more additional agents disclosed in the compositions forming state of the art. These additional agents may pose some secondary problems of their own such as the possibility of altering the taste, flavor impact or stability of the compositions.
- The present invention is a non-obvious solution to the problem, whilst still retaining the essential functional and consumer-relevant attributes of oral care compositions. The problem has been solved by identifying the use of antimicrobial material. Compared to the solutions disclosed in prior art, the solution in the present invention lies in the inclusion of the composite material which acts as a carrier of the cationic antimicrobial agent. The composite material is based on an inert material which does not affect the important properties of the compositions. In
WO14102032A1 - It is preferred that median particle size (D50) of this material is 0.1 to 10 µm, more preferably 0.4 to 1 µm and most preferably 0.5 to 0.8 µm. Without being bound by theory, it is believed that this makes more effective use of the antimicrobial agent, thereby providing opportunity for substantial reduction in dosage of the antibacterial agent. While conventional antibacterial agents need an optimised dosage of 0.2 to 0.5 wt%, the antibacterial agent, delivered in the form of the bipolar antibacterial material, is effective even at an (actual) dosage of 0.02 wt% of the oral care compostion, insofar as the antimicrobial effect is concerned.
- Lower particle size also provides an effective mechanism for increased the loading of the antibacterial agent, if so desired. Particle size distribution (D50) is also known as the median diameter or the medium value of the particle size distribution, it is the value of the particle diameter at 50 percent in the cumulative distribution. For example, if D50 is 5.8 µm, then 50 % of the particles in the sample are larger than 5.8 µm and 50 percent smaller than 5.8 µm. D50 is usually used to represent the particle size of group of particles. The D50 is the size in microns that splits the distribution with half above and half below this diameter.
- It is preferred that in the bipolar composite material comprising a clay, the precursor of the clay is an asymmetric 1:1 clay particle. Preferred 1:1 clays include kaolinite and serpentine subgroups of minerals. The species included within the kaolinite subgroup include but are not limited to kaolinite, dickite, halloysite and nacrite. The species within the serpentine subgroup include but are not limited to chrysolite, lizardite, and amesite. Alternatively, it is also preferred that the precursor of the clay is an asymmetric 2:1:1 clay particle. Preferred 2:1:1 clays include chlorite group of minerals. The chlorite comprises tetrahedral-octahedral-tetrahedral sheets like 2:1 clays, with an extra weakly bound brucite like layer between tetrahedral layers. The tetrahedral sheet preferably comprises coordinating tetrahedral cations of silicon. The tetrahedral sheet may also include isomorphously substituted coordinating tetrahedral cations which are not silicon. Isomorphously substituted coordinating tetrahedral cations include, but are not limited to, cations of aluminum, iron or boron.
- It is preferred that the octahedral sheet has coordinating octahedral cations of aluminum. The octahedral sheet may also comprise isomorphously substituted coordinating octahedral cations which are not aluminium. Isomorphously substituted coordinating octahedral cations include cations of magnesium and iron. The antimicrobial agent is attached to the coordinating cations on the exterior side of one of the external surface planes. Accordingly, the antimicrobial agent is attached to coordinating cations on the exterior side of the tetrahedral sheet. Alternatively, the antimicrobial molecule is attached to the coordinating cations on the exterior side of the octahedral sheet. Coordinating cations on the exterior side of each of the tetrahedral and the octahedral surface sheets are attached to the antimicrobial agent, with the proviso that the antimicrobial agent attached to the coordinating cations on the exterior side of the tetrahedral surface sheet is not identical to the molecule attached to the coordinating cations on the exterior side of the octahedral surface sheet. The antimicrobial agent is preferably attached to the coordinating cations on the external surface of the octahedral surface plane and is not preferably attached to coordination cations of non-exterior tetrahedral or octahedral plane or on the interior side of the surface sheets.
- It is preferred that the ratio of the clay: antimicrobial agent is from 1:0.001 to 1:1, more preferably from 1:0.001 and 1:0.1 parts by weight of the bipolar composite material.
- It is preferred that in the antimicrobial material, the antibacterial agent is attached to coordinating cations on the external surface of the octahedral surface plane.
- It is preferred that oral care compositions of the invention comprise 0.1 to 10 wt% of the bipolar antimicrobial material, more preferably 0.5 to 5 wt% material.
- Preferably the quaternary ammonium compound is one or more of cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), benzethonium chloride, cetrimide, quaternium, tetrabutyl ammonium bromide, undecylenamido propyltrimonium methosulphate, methylbenzethonium chloride, cetethyldimonium bromide, cetromonium tosylate, cocotrimonium chloride, dodecylbenzyltrimonium chloride, lauryl isoquinolium bromide, laurylpyridinium chloride, dequalinium chloride or domiphen bromide.
- It is particularly preferred that the antimicrobial agent cetylpyridinium chloride (CPC). Without being bound by theory, it is believed that the primary activity is linked to the cationic charge of its amine group. Thus, cetylpyridinium chloride is attracted to and binds to negatively-charged protein moieties on the cell membrane or cell wall of the microorganism and to tooth surfaces which are also typically negatively charged. The resulting attachment to microorganisms disrupts the cell wall structure causing leakage of the intracellular fluids, eventually killing the associated microorganism. However, as disclosed earlier and in particular with reference to cetylpyridinium chloride, its tendency to stain the teeth has largely been responsible for the lack of popularity of oral compositions which contain for example and in particular, CPC.
- It is particularly preferred that precursor of the clay is a 1:1 clay particle. Further preferably the precursor of the clay is kaolinite. It is particularly preferred that the antimicrobial quaternary ammonium compound is cetyl pyridinium chloride. It is further particularly preferred that when the precursor of the clay is kaolinite, the antimicrobial quaternary ammonium compound is cetyl pyridinium chloride.
- The description of preferred features applies mutatis mutandis to the other aspects of the invention.
- It is preferred that the oral care composition is a toothpaste. Alternatively, the oral care composition is a mouthwash. Other known forms include toothpowder, chewing gums and lozenges, strips and gels.
- It is preferred that when the oral care composition according to the invention is a toothpaste, the toothpaste comprises at least one of calcium-based abrasive or silica-based abrasive.
- Toothpastes are also known as dentifrices. The term "dentifrice" generally denotes formulations which are used to clean the surfaces of the oral cavity. The dentifrice is an oral composition that is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is applied to the oral cavity, used to treat the oral cavity and then expectorated. Typically, the dentifrice is used in conjunction with a cleaning implement such as a toothbrush, usually by applying it to the bristles of the toothbrush and then brushing the accessible surfaces of the oral cavity. Preferably the dentifrice is in the form of a paste or a gel (or a combination thereof).
- An oral care composition according to the invention will usually contain a liquid continuous phase in an amount of from 40 to 99% by weight based on the total weight of the dentifrice. Such a liquid continuous phase will typically comprise a mixture of water and polyhydric alcohol in various relative amounts, with the amount of water generally ranging from 10 to 45% by weight (based on the total weight of the dentifrice) and the amount of polyhydric alcohol generally ranging from 30 to 70% by weight (based on the total weight of the dentifrice).
- Humectants are generally included in toothpastes for a soft, supple mouth feel. Humectants also reduce the tendency of toothpastes to lose moisture. Preferred toothpaste compositions contain 3.5 to 40 wt% humectants. Further preferred compositions have 10 to 40 wt%, more particularly 10 to 20 wt% humectants. A particularly preferred humectant is sorbitol, generally available as 70% aqueous solution. Other preferred humectants include glycerine, maltitol and xylitol. More preferred toothpastes contain glycerine and sorbitol for a lubricated mouth feel, but their cumulative levels should not exceed the disclosed upper limit. Lower humectant content provides an effective way to reduce the cost of the product.
- An oral care composition according to the invention will generally contain further ingredients to enhance performance and/or consumer acceptability such as abrasive cleaning agent, binder or thickening agent, and surfactant.
- For example, a dentifrice will usually comprise an abrasive cleaning agent in an amount of from 3 to 75% by weight based on the total weight of the dentifrice. Suitable abrasive cleaning agents include silica xerogels, hydrogels and aerogels and precipitated particulate silicas; calcium carbonate, dicalcium phosphate, tricalcium phosphate, calcined alumina, sodium and potassium metaphosphate, sodium and potassium pyrophosphates, sodium trimetaphosphate, sodium hexametaphosphate, particulate hydroxyapatite and mixtures thereof. Examples of abrasives include abrasive amorphous silica particles which have a weight mean particle size (d50) ranging from 3 to 15 microns. Preferred abrasive amorphous silica particles for use in the composition of the invention have a weight mean particle size in the range 3 to 6 microns. Preferably, the abrasive amorphous silica particles employed are precipitated silica. Suitable precipitated silicas for use as abrasive amorphous silica particles in the invention are commercially available and include those marketed by PQ Corporation under the trade names SORBOSIL® AC 43, AC77, AC35 and SORBOSIL® AC 33. Mixtures of any of the above described materials may also be used. The level of abrasive amorphous silica particles (as defined above) generally ranges from 0.05 to 5%, preferably from 0.1 to 3%, more preferably from 0.2 to 0.8%, by total weight abrasive amorphous silica particles (as defined above) based on the total weight of the composition.
- Preferably the compositions of the invention comprise calcium-based abrasive. A particularly preferred abrasive is fine ground natural chalk (FGNC). It is obtained from limestone or marble. FGNC may also be modified chemically or physically by coating during or after milling by heat treatment. Typical coating materials include magnesium stearate and oleate. The morphology of FGNC may also be modified during the milling process by using different milling techniques, for example, ball milling, air-classifier milling or spiral jet milling. FGNC can be used as the sole calcium containing abrasive. However, FGNC can also be used with other calcium containing abrasives to balance the abrasion.
- Other preferred calcium containing abrasives include dicalcium phosphate (DCP), calcium pyrophosphate and precipitated calcium carbonate (PCC). When a combination of Calcium containing abrasives is used, it is preferred that FGNC is 35 to 100 %, more preferably 75 to 100 % and especially from 95 to 100 % of the total abrasive. In such cases, the balance, most preferably, is PCC.
- Furthermore, the compositions of the invention preferably comprise a binder or thickening agent in an amount of from 0.5 to 10% by weight based on the total weight of the dentifrice. Suitable binders or thickening agents include carboxyvinyl polymers (such as polyacrylic acids cross-linked with polyallyl sucrose or polyallyl pentaerythritol), hydroxyethyl cellulose, hydroxypropyl cellulose, water soluble salts of cellulose ethers (such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose), natural gums (such as carrageenan, gum karaya, guar gum, xanthan gum, gum arabic, and gum tragacanth), finely divided silicas, hectorites, colloidal magnesium aluminium silicates and mixtures thereof.
- Furthermore, the compositions of the invention preferably comprise a surfactant in an amount of from 0.2 to 10% by weight based on the total weight of the dentifrice. Suitable surfactants include anionic surfactants, such as the sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl sulphates (for example sodium lauryl sulphate), C8 to C18 alkyl sulphosuccinates (for example dioctyl sodium sulphosuccinate), C8 to C18 alkyl sulphoacetates (such as sodium lauryl sulphoacetate), C8 to C18 alkyl sarcosinates (such as sodium lauryl sarcosinate), C8 to C18 alkyl phosphates (which can optionally comprise up to 10 ethylene oxide and/or propylene oxide units) and sulphated monoglycerides. Other suitable surfactants include nonionic surfactants, such as optionally polyethoxylated fatty acid sorbitan esters, ethoxylated fatty acids, esters of polyethylene glycol, ethoxylates of fatty acid monoglycerides and diglycerides, and ethylene oxide/propylene oxide block polymers. Other suitable surfactants include amphoteric surfactants, such as betaines or sulphobetaines. Mixtures of any of the above described materials may also be used.
- It is preferred that oral care compositions of the invention include a smectite clay which is in addition to the clay present by way of the bipolar antimicrobial material. Smectites constitute a group in the class of natural aluminosilicate minerals known as phyllosilicates or layered silicates. Preferred smectite clay is selected from montmorillonites (bentonites, hectorites and derivatives thereof); purified aluminium magnesium silicates (various grades are commercially available as VEEGUM(R)from R. T. Vanderbilt Company); purified sodium magnesium silicates (commercially available as LAPONITE(R) in various grades); organically modified smectites including tetra alkyl and/or trialkyl ammonium smectites (organically modified montmorillonite clays) such as quaternium-18 bentonite, quaternium-18 hectorite, stearalkonium bentonite and stearalkonium hectorite/ and mixtures thereof. Aluminium magnesium silicate clays are particularly preferred. An example is VEEGUM(R) HV. The clay tends to swell when exposed to water. Preferred toothpaste compositions contain 0.2 to 3 wt percent clay. More preferred compositions include 0.5 to 1 wt percent clay.
- The smectite clay not only plays a role in sensory profile as is believed, but it also plays a role in thickening the composition, as the reduced content of thickening silica otherwise leads to a product with lower viscosity.
- Oral care compositions of the invention further preferably comprise a zinc salt, preferably zinc sulphate or zinc chloride, more preferably zinc sulphate heptahydrate. Preferably the level of zinc salt is from 0.05 to 1.0 wt% of the total composition more preferably from 0.1 to 0.5 wt%.
- Compositions of the invention may comprise a preservative, a preferred preservative is sodium benzoate.
- Preferably the level of preservative is from 0.1 to 1 wt% of the total composition. It is preferred that pH of the composition at 20 °C is from 4 to 10, more preferably 7 to 9.
- The compositions of the invention may also comprise a deposition aid. The term "deposition aid" in the context of this invention generally means a material which further aids deposition of whitening agents from the composition. An example is polystyrene sulphonates. Another example is Gantrez® polymers.
- The term "mouthwash" generally denotes liquid formulations which are used to rinse the surfaces of the oral cavity and provide the user with a sensation of oral cleanliness and refreshment. The mouthwash is an oral composition that is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is applied to the oral cavity, used to treat the oral cavity and then expectorated.
- A mouthwash composition will usually contain an aqueous continuous phase. The amount of water generally ranges from 70 to 99% by weight based on the total weight of the mouthwash.
- A mouthwash composition according to the invention will generally contain further ingredients to enhance performance and/or consumer acceptability, such as the humectants and surfactants mentioned above for dentifrices. The amount of humectant generally ranges from 5 to 20% by weight based on the total weight of the mouthwash and the amount of surfactant generally ranges from 0.1 to 5% by weight based on the total weight of the mouthwash.
- Compositions of the present invention (such as in particular dentifrices or mouthwashes) may also contain further optional ingredients customary in the art such as fluoride ion sources, anticalculus agents, buffers, flavouring agents, sweetening agents, colouring agents, opacifying agents, preservatives, antisensitivity agents and antimicrobial agents.
- Use of the composition in the context of this invention typically involves application of the composition to the oral cavity, for a recommended time, before being expectorated. The preferred time application time being from 10 to 60 seconds.
- Various examples illustrative of the invention are presented as follows and are no way to be considered as limiting the scope of the invention.
- Two toothpaste compositions were prepared. The compositions are detailed in Table 1.
Table 1 Ingredient/wt% Toothpaste Composition Control 1 Inventive calcium carbonate 40 40 sorbitol (70%) 30 30 Veegum™ HV 0.8 0.8 Bipolar composite material* -- 1.5 Kaolinite 1.5 -- seme 0.5 0.5 sodium lauryl sulphate 2.5 2.5 sodium silicate 1.7 1.7 water and minors to 100 to 100 Note*:
(i) *The bipolar composite material contained kaolinite and cetyl pyridinuim chloride in an amount which made the final amount of CPC to 0.045 wt% by weight of the total toothpaste composition. D50 of the material was 0.5 µm. The material was made in accordance with Example 1 ofUS2012/0177712 A1 (Unilever ).
(ii) As cetyl pyridinium chloride (CPC) is highly unstable and prone to react with sodium lauryl sulphate, no experiments could be carried out in a composition which contained inter alia, CPC but not in the form of the bipolar composite material
(iii) Therefore, the experiment was repeated with an additional control composition as referred to in Table 2. - The compositions were subjected to in-vitro assay following the Bovine Tooth Model, (without brushing). The procedure was as follows:
This model utilizes extracted bovine teeth mounted on polyacrylate material. Bovine teeth were first bleached with dilute peroxide followed by washing with water. The bleached teeth were incubated with saliva for four hours and dried. The teeth were then imaged to determine their baseline color values (L*a*b*) using digital photography using the white light imaging system (Fuji 2000 Camera). L* represents lightness on the y axis, a* represents chroma (red-green) on the x axis, and b* represents chroma (yellow-blue) on the z axis. The teeth were then incubated in saliva for 18 hours to generate a mature coating of pellicle thereon. The saliva was then removed and the teeth were treated with a slurry of the concerned toothpaste (containing no antimicrobials) for two minutes. - The toothpaste slurry was removed and the teeth were washed with water for one minute. The teeth specimens were then ready for treatment. The teeth specimen were treated with CPC solution (positive control), water (negative control) or CPC test rinse solution for one minute in the presence of saliva. The teeth were then incubated with saliva for 20 minutes at 35 °C. Each specimen was subsequently treated with freshly made aqueous solution of tea for 15 minutes, followed by another washing and incubation with saliva for 20 minutes. A total of six treatment cycles were carried out. After five cycles, the teeth were dried and the L*a*b* values were measured again using photo imaging. Changes in the individual L*, a*, and b* components (ΔE) were calculated by subtracting the L*a*b* measurements of treated teeth from the L*a*b* measurements of untreated and unstained teeth. The total color change (ΔE) was calculated as the square root of the sum of the square of the ΔE values. A greater value of ΔE value indicates that the difference between untreated and treated teeth is less. In other words, it indicates that more of the stain remains on the teeth. Conversely, lower value of ΔE indicates that less amount of stain remains on the teeth after the treatment and therefore, the concerned composition is more likely to find consumer acceptance as compared to the ones where the ΔE is comparatively more.
- All tests were carried out with a replicate of four teeth. The observations are summarised in Table 2.
Table 2 Toothpaste Compositions (Additional Control) Marketed gel toothpaste (Dentosan®) containing 0.2 wt% Chlorhexidine Control 1 Inventive ΔE 3.4 2.2 2.1 - The observation about the additional control composition underlines the fact that oral care compositions containing cationic antimicrobial agents (in this case, toothpastes) can stain the teeth. The observation about the Control 1 composition is not surprising considering the fact that this composition did not contain any cationic antimicrobial agent. Therefore, it is expected that the ΔE value would be lower than the Additional Control composition.
- However, the observation with the ΔE value of the inventive composition is that the ΔE value is the same as that of the corresponding Control Composition 1. This was a surprising observation because the expectation was that the presence of cetyl pyridinium chloride (in the form of the antimicrobial material) would have led to an increase in the ΔE value to somewhere close to the value observed in the case of the Additional Control composition. Therefore the technical effect of the antimicrobial material was wholly unexpected and surprising. In view of this, it amounts to new use of the material.
Claims (11)
- A bipolar composite material comprising:(i) a clay whose precursor is an asymmetric 1:1 or 2:1:1 clay particle, comprising alternating tetrahedral and octahedral sheets terminating with a tetrahedral sheet at one external surface plane and an octahedral sheet at another; and,(ii) antimicrobial quaternary ammonium compound attached to a coordinating cation on one of said external surface planes,for use in an oral care composition, to control staining of teeth due to said ammonium compound.
- A bipolar composite material for use according to claim 1 in which the antimicrobial quaternary ammonium compound is attached to coordinating cations on the external surface of the octahedral surface plane.
- A bipolar composite material for use according to claim 1 or 2 wherein the ratio of clay to said antimicrobial quaternary ammonium compound, in said material, is from 1:0.001 to 1:1 parts by weight.
- A bipolar composite material for use according to any of claims 1 to 3 which is present in the oral care composition at a level from 0.1 to 10 wt % of the total composition.
- A bipolar composite material for use according to any of claims 1 to 4 wherein median diameter (D50) of said materials is 0.1 to 10 µm.
- A bipolar composite material for use according to any of claims 1 to 5 wherein said quaternary ammonium compound is one or more of cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), benzethonium chloride, cetrimide, quaternium, tetrabutyl ammonium bromide, undecylenamido propyltrimonium methosulphate, methylbenzethonium chloride, cetethyldimonium bromide, cetromonium tosylate, cocotrimonium chloride, dodecylbenzyltrimonium chloride, lauryl isoquinolium bromide, laurylpyridinium chloride, dequalinium chloride or domiphen bromide.
- A bipolar composite material for use according to any of claims 1 to 6 wherein when said precursor is an asymmetric 1:1 clay particle, said clay belongs to kaolinite or serpentine subgroup.
- A bipolar composite material for use according to any of claims 1 to 6 wherein, when said precursor is an asymmetric 2:1:1 clay particle, said clay belongs to chlorite subgroup.
- A bipolar composite material for use according to any of claims 1 to 8 in which the oral care composition is a toothpaste.
- A bipolar composite material for use according to any one of claims 1 to 8 in which the oral care composition comprises calcium-based abrasive
- A bipolar composite material for use according to any one of claims 1 to 8 which the oral care composition is a mouthwash.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17186556 | 2017-08-17 | ||
PCT/EP2018/069384 WO2019034352A1 (en) | 2017-08-17 | 2018-07-17 | Method of controlling staining of teeth due to cationic antimicrobial agent |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3668606A1 EP3668606A1 (en) | 2020-06-24 |
EP3668606B1 true EP3668606B1 (en) | 2023-09-13 |
Family
ID=59699498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18739865.6A Active EP3668606B1 (en) | 2017-08-17 | 2018-07-17 | Method of controlling staining of teeth due to cationic antimicrobial agent |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3668606B1 (en) |
CN (1) | CN111093775B (en) |
WO (1) | WO2019034352A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021078685A1 (en) | 2019-10-23 | 2021-04-29 | Unilever Ip Holdings B.V. | Method of reducing dental hypersensitivity |
BR112022023885A2 (en) * | 2020-06-24 | 2022-12-27 | Unilever Ip Holdings B V | COMPOSITIONS, NON-THERAPEUTIC USE OF A COMPOSITION AND NON-THERAPEUTIC METHOD OF TREATMENT OF BAD BREATH |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4370314A (en) * | 1975-12-08 | 1983-01-25 | Colgate-Palmolive Company | Oral composition containing antibacterial agent |
MX170421B (en) | 1988-11-15 | 1993-08-20 | Colgate Palmolive Co | IMPROVEMENTS TO ORAL ANTIBACTERIAL COMPOSITION |
JP5765934B2 (en) | 2009-12-28 | 2015-08-19 | サンスター株式会社 | Oral composition |
JP2011148706A (en) | 2010-01-19 | 2011-08-04 | Sunstar Inc | Oral composition |
JP5804307B2 (en) | 2010-03-03 | 2015-11-04 | サンスター株式会社 | Oral composition |
US10123953B2 (en) | 2012-06-21 | 2018-11-13 | The Procter & Gamble Company | Reduction of tooth staining derived from cationic antimicrobials |
CN104869976A (en) * | 2012-12-27 | 2015-08-26 | 荷兰联合利华有限公司 | Oral care composition having an adduct of clay and antibacterial agent |
KR101682642B1 (en) * | 2014-10-28 | 2016-12-07 | (주)제주사랑농수산 | Toothpaste Composition for Whitening Tooth Using Scoria Powder |
-
2018
- 2018-07-17 CN CN201880060198.9A patent/CN111093775B/en active Active
- 2018-07-17 EP EP18739865.6A patent/EP3668606B1/en active Active
- 2018-07-17 WO PCT/EP2018/069384 patent/WO2019034352A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN111093775B (en) | 2022-11-08 |
EP3668606A1 (en) | 2020-06-24 |
CN111093775A (en) | 2020-05-01 |
WO2019034352A1 (en) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI468179B (en) | Oral care regimen | |
US9867764B2 (en) | Oral care composition | |
EP2938318B1 (en) | Oral care composition having an adduct of clay and antibacterial agent | |
EP2600938B1 (en) | Oral care compositions | |
EP3393426B1 (en) | Toothpaste composition | |
CN110997071B (en) | Method for promoting tooth remineralization | |
US20080274065A1 (en) | Oral Care Regimen | |
US11246809B2 (en) | Composition | |
EP3668606B1 (en) | Method of controlling staining of teeth due to cationic antimicrobial agent | |
EP3651722B1 (en) | A composite material for whitening teeth and composition comprising the same | |
CA1170187A (en) | Synthetic zeolite-containing dentifrice | |
WO2023094383A1 (en) | Oral care composition comprising a bipolar composite material | |
EP3352723B1 (en) | Oral care composition | |
AU2019388767B2 (en) | Oral care compositions comprising charcoal | |
JPS6145606B2 (en) | ||
WO2022184875A1 (en) | Oral care composition | |
WO2020173917A1 (en) | Oral care composition | |
WO2022059642A1 (en) | Dentifrice composition | |
WO2021048041A1 (en) | Oral care composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200915 |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNILEVER IP HOLDINGS B.V. Owner name: UNILEVER GLOBAL IP LIMITED |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNILEVER IP HOLDINGS B.V. Owner name: UNILEVER GLOBAL IP LIMITED |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230516 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230731 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018057486 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231213 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231214 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1610667 Country of ref document: AT Kind code of ref document: T Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240113 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018057486 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230913 |
|
26N | No opposition filed |
Effective date: 20240614 |